# US 2004/0063188 A1 · Kit for treating gastrointestinal tract

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0063188 A1
- Document ID: US20040063188A1
- Status: Published application
- Kind: A1
- Application number: 10/368,046
- Filed: 2003-02-14
- Published: 2004-04-01
- Earliest claimed: 2002-02-14
- Assignees: Novavax, Inc.
- Inventors: Robin A. Robinson; Mark W. Thompson
- Web page: https://patentgrep.com/patent/US20040063188A1

## CPC

- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5258: {Virus-like particles}
- C12N 2510/02: Cells for production
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/20023: Virus like particles [VLP]
- C12N 2720/12322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods for isolation and purification or recombinant gene products are disclosed. In particular, methods for isolation and purification of extracellular and intracellular viral gene products, including virus-like particles, are disclosed herein.

## Claims

### Claim 1

A process for purifying a recombinant extracellular virus-like particle comprising the steps of:
(a) harvesting a cell suspension comprising cells containing a plurality of virus-like particles to produce a harvested supernatant;
(b) clarifying the harvested supernatant;
(c) concentrating the clarified supernatant;
(e) diafilterning the concentrated supernatant; and
(f) recovering the purified recombinant virus-like particle.

### Claim 2 (depends on 1)

The process of claim 1, wherein the clarifying step comprises centrifuging the harvested supernatant, the concentrating step comprises ultrafiltering the clarified supernatant, and the dialyzing step comprises ultrafiltering the concentrated supernatant.

### Claim 3 (depends on 1)

The process of claim 1, wherein the cells are from a cell line designated ATCC PTA-4047.

### Claim 4 (depends on 3)

The process of claim 3, wherein the cells express a plurality of recombinant viral capsid proteins that self-assemble into a virus-like particle secreted from the cell.

### Claim 5 (depends on 4)

The process of claim 4, wherein the cells are infected with at least one baculovirus that expresses one or more of the recombinant viral capsid proteins.

### Claim 6 (depends on 5)

The process of claim 5, further comprising the step of inactivating baculovirus in the clarified supernatant.

### Claim 7 (depends on 6)

The process of claim 6, wherein the inactivating step comprises contacting the clarified supernatant with a nonionic detergent, a nonionic surfactant, and/or irradiating with an ultraviolet light.

### Claim 8 (depends on 1)

The process of claim 1, wherein the virus-like particle comprises a virus-like particle of a human papillomavirus.

### Claim 9 (depends on 1)

The process of claim 1, wherein the amount of recovered intact virus-like particles is determined by analytical size exclusion chromatography.

### Claim 10

A process for purifying an intracellular recombinant papillomavirus virus-like particle, comprising the steps of:
(a) harvesting a cell suspension comprising cells containing the recombinant papillomavirus L1 virus-like particle to produce harvested cells;
(b) disrupting the harvested cells to produce cell lysates containing the recombinant papillomavirus L1 virus-like particle;
(c) clarifying the cell lysates to produce a supernatant comprising the recombinant papillomavirus L1 virus-like particle;
(d) concentrating the recombinant papillomavirus virus-like particle in the supernatant;
(e) diafiltering the concentrated recombinant papillomavirus virus-like particle; and
(f) recovering partially-purified intracellular recombinant papillomavirus virus-like particles.

### Claim 11 (depends on 10)

The process of claim 10, wherein the harvesting step comprises centrifuging the cell suspension, the disrupting step comprises sonicating the harvested cells without solubilizing their proteosomes, clarifying step comprises centrifuging the disrupted cells, concentrating step comprises ultrafiltering the recombinant papillomavirus L1 virus-like particle in the supernatant, and the diafiltering step comprises ultrafiltering the concentrated recombinant papillomavirus L1 virus-like particle.

### Claim 12 (depends on 10)

The process of claim 10, wherein the cells comprise insect cells, mammalian cells, or yeast cells.

### Claim 13 (depends on 12)

The process of claim 12, wherein the cells are insect cells.

### Claim 14 (depends on 13)

The process of claim 13, wherein the insect cells are from a cell line designated ATCC PTA-4047.

### Claim 15 (depends on 14)

The process of claim 14, wherein the cells express a plurality of recombinant viral capsid proteins that self-assemble into the recombinant papillomavirus virus-like particle.

### Claim 16 (depends on 14)

The process of claim 14, wherein the cells are infected with at least one baculovirus that expresses one or more of the recombinant papillomavirus proteins.

### Claim 17 (depends on 16)

The process of claim 16 further comprising the step of inactivating baculovirus in the clarified supernatant.

### Claim 18 (depends on 17)

The process of claim 17, wherein the inactivating step comprises contacting the clarified supernatant with a nonionic detergent, a nonionic surfactant, and/or irradiating with an ultraviolet light.

### Claim 19 (depends on 10)

The process of claim 10, wherein the recombinant pappilomavirus virus-like particle comprises a virus-like particle of a human papillomavirus.

### Claim 20 (depends on 10)

The process of claim 10, wherein the amount of the recombinant papillomavirus virus-like particle is determined by a size exclusion chromatography.

### Claim 21 (depends on 19)

The process of claim 19, wherein the human papillomavirus comprises HPV-16, HPV-18, HPV-45, HPV-31, HPV-33, HPV-35, HPV-51, HPV-52, HPV-6, HPV-11, HPV-42, HPV-43, and HPV-44.

### Claim 22 (depends on 10)

The process of claim 10, wherein the recombinant papillomavirus virus-like particle comprises human papillomavirus L1 virus-like particle.

### Claim 23

A process for purifying a recombinant papillomavirus virus-like particle, comprising the steps of:
(a) binding the papillomavirus virus-like particle to an ion exchange chromatographic resin;
(b) eluting the bound virus-like particle; and
(c) recovering the purified recombinant papillomavirus virus-like particle.

### Claim 24 (depends on 23)

The process of claim 23, wherein the ion exchange chromatography is a cation exchange adsorptive chromatography and eluting is achieved by a pH gradient.

### Claim 25 (depends on 23)

The process of claim 23, wherein the chromotographic resin comprises a molecule having an exposed amine group.

### Claim 26 (depends on 23)

The process of claim 23, wherein the ion exchange chromatography is an anion exchange displacement chromatography and eluting is achieved by a low molecular weight polymer.

### Claim 27 (depends on 26)

The process of claim 26, wherein the chromotographic resin comprises a molecule having an exposed carboxy group.

### Claim 28

A process for purifying a recombinant papillomavirus virus-like particle comprising the steps of
(a) binding the papillomavirus virus-like particle to an affinity chromatographic resin,
(b) eluting the bound virus-like particle with a salt gradient; and
(c) recovering the purified recombinant papillomavirus virus-like particle.

### Claim 29 (depends on 28)

The process of claim 28, wherein the chromatographic resin comprises a heparin-like chromatographic resin.

### Claim 30 (depends on 28)

The process of claim 28, wherein the chromatographic resin comprises a heparin agarose, heparin sulfate glycans, glycoaminoglycans, α6β1 integrin, (α6β4 integrin, syndecan 1, or a combination thereof.

### Claim 31 (depends on 28)

The process of claim 28, wherein the chromatographic resin comprises heparin.

### Claim 32

A process for purifying a virus-like particle, comprising the steps of:
(a) binding the virus-like particle to a cation exchange adsorptive chromatographic resin;
(b) eluting, with a pH gradient, the virus-like particle bound to the cation exchange chromatographic resin;
(c) binding the virus-like particle eluted in the pH-gradient eluting step to an affinity chromatographic resin;
(d) eluting, with a salt gradient, the virus-like particle bound to the affinity chromatographic resin;
(e) binding the virus-like particle eluted in step (d) to an anion exchange chromatographic resin; and
(f) displacing the virus-like particle bound to the anion exchange chromatographic resin of step (e) with a low molecular weight polymer.
(g) recovering the purified virus-like particle.

### Claim 33 (depends on 32)

The process of claim 32, wherein the cells comprise insect cells, mammalian cells, or yeast cells.

### Claim 34 (depends on 33)

The process of claim 33, wherein the cells are insect cells.

### Claim 35 (depends on 34)

The process of claim 34, wherein the cells are from a cell line designated ATCC PTA-4047.

### Claim 36 (depends on 35)

The process of claim 35, wherein the cells express a plurality of recombinant viral capsid proteins that self-assemble into a virus-like particle.

### Claim 37 (depends on 32)

The process of claim 32, wherein the cells express the virus-like particle extracellularly.

### Claim 38 (depends on 34)

The process of claim 34, wherein the cells are infected with at least one baculovirus that expresses one or more of the recombinant viral capsid proteins.

### Claim 39 (depends on 32)

The process of claim 32, wherein the virus-like particle comprises a virus-like particle of a human papillomavirus.

### Claim 40 (depends on 32)

The process of claim 32, wherein the amount of recovered virus-like particles is determined by a size exclusion chromatography.

### Claim 41 (depends on 32)

The virus-like particle of claim 32, having a diameter of about 40 nm to about 55 nm.

### Claim 42 (depends on 32)

The virus-like particle of claim 32, comprising a L1 capsid protein with a molecular weight of approximately 50-65 kDa.

### Claim 43 (depends on 40)

The virus-like particle of claim 40, displaying conformational epitopes eliciting neutralizing antibodies for papillomavirus.

### Claim 44

A process for purifying an intracellular recombinant papillomavirus chimeric virus-like particle from cells, comprising the steps of:
(a) harvesting a cell suspension comprising co-infected cells containing the intracellular recombinant papillomavirus chimeric virus-like particle;
(b) resuspending the harvested cells in a buffer comprising a protease inhibitor;
(c) disrupting the resuspended cells to produce cell lysates containing recombinant papillomavirus chimeric virus-like particle;
(d) clarifying the cell lysates to produce a supernatant comprising the recombinant papillomavirus chimeric virus-like particle;
(e) concentrating the recombinant papillomavirus chimeric virus-like particle in the supernatant;
(f) diafiltering the concentrated recombinant papillomavirus chimeric virus-like particle; and
(g) recovering the partially-purified recombinant papillomavirus chimeric virus-like particle.

### Claim 45 (depends on 44)

The process of claim 44, wherein the harvesting step comprises centrifuging the cell suspension, the disrupting step comprises sonicating the re-suspended cells without solubilizing their proteosomes, the clarifying step comprises centrifuging the disrupted cells, the concentrating step comprises ultrafiltering the clarified supernatant, and the diafiltering step comprises ultrafiltering the concentrated supernatant.

### Claim 46 (depends on 44)

The process of claim 44, wherein the cells comprise insect cells, mammalian cells, or yeast cells.

### Claim 47 (depends on 46)

The process of claim 46, wherein the cells are insect cells.

### Claim 48 (depends on 47)

The process of claim 47, wherein the insect cells are from a cell line designated ATCC PTA-4047.

### Claim 49 (depends on 48)

The process of claim 48, wherein the cells express a plurality of recombinant viral capsid proteins that self-assemble into a recombinant papillomavirus virus-like particle.

### Claim 50 (depends on 14)

The process of claim 14, wherein the cells are infected with at least one baculovirus that expresses one or more of the recombinant papillomavirus proteins.

### Claim 51 (depends on 50)

The process of claim 50, further comprising the step of inactivating the baculovirus in the clarified supernatant.

### Claim 52 (depends on 51)

The process of claim 51, wherein the inactivating step comprises treating the clarified supernatant with a nonionic surfactant, a nonionic detergent, and/or irradiating the clarified supernatant with ultraviolet light.
